reports
Tempest Security AB: 1 director
A director at Tempest Security AB bought 18,819 shares at 14.303SEK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Tempest Reports Second Quarter 2021 Financial Results and Provides Cor...
Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights Closed merger transaction resulting in public listing (TPST)Closed $30M PIPE, extending runway into Q1’23Advancing TPST-1495 and TPST-1120 into targeted patient populationsAdvanced TREX-1 program to potent lead series with in vivo efficacy SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today rep...
Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of ...
Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of Ronit Simantov, M.D., a seasoned and accomplished industry veteran as well as hematology and oncology expert, to the company’s board of directors. Dr. Simantov brings more than 20 years of experience in oncology resear...
Tempest to Participate in William Blair 2021 Biotech Focus Conference
Tempest to Participate in William Blair 2021 Biotech Focus Conference SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiting, M.D., Ph.D., chief medical officer, will participate in a webcast panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on Wednesday, July 14, 2021 at 2:10 p.m. ET. To ac...
Tempest Announces Appointment of Christine Pellizzari to its Board of ...
Tempest Announces Appointment of Christine Pellizzari to its Board of Directors SOUTH SAN FRANCISCO, July 01, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced the appointment of 20-year industry veteran Christine Pellizzari to the company’s Board of Directors. “We are very excited to welcome Christine to our Board of Directors at this important point for Tempest as a newly public company,” said Steve...
Tempest Closes Merger with Millendo and Completes PIPE Financing
Tempest Closes Merger with Millendo and Completes PIPE Financing SOUTH SAN FRANCISCO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced today the closing of its merger with Millendo Therapeutics, Inc. (“Millendo”). Tempest’s stock will commence trading on June 28, 2021 on the Nasdaq Global Select Market under the trading symbol “TPST.” In support of the merger, Tempest secured investments f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.